0.00Open0.80Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover7113.30%IV1.32%PremiumMay 17, 2024Expiry Date0.92Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.4388Delta0.0726Gamma11.35Leverage Ratio-43.7798Theta0.0000Rho-4.98Eff Leverage0.0003Vega
Arcutis Biotherapeutics Stock Discussion
I expect this to do well today based on its good ER results
NEWS
Positive
Q1 2024 net product revenues of $21.6M, a 675% increase from Q1 2023.
ZORYVE cream and foam contributed $15M and $6.5M to revenues respectively.
Significant demand for ZORYVE products with 208,000 cream prescriptions and 46,000 foam prescriptions.
Raised $172.5M from a public offering.
Strategic licensing agreement in Japan with Sato Pharmaceutical.
FDA accepted sNDA for roflumilast cream for atopic dermatitis with a PDUFA date of July 7, 2024.
Ca...
up a lot, down a lot
Benzinga· 3 mins ago
No comment yet